Immune cells armed with antibody take on pancreatic cancer

NCT ID NCT03269526

Completed Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tested a new treatment called EGFR BATs for people with advanced pancreatic cancer. The treatment uses a patient's own immune cells, armed with a special antibody, to target cancer cells. The study included 22 participants who had already received chemotherapy. The goal was to check safety and see if it could improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EGFR BATs (immune cells armed with a bispecific antibody)
What this could lead to: If successful, this could offer a new treatment option to extend survival for people with advanced pancreatic cancer.
What could go wrong: This is an early-phase trial with only 22 participants, so results may not apply broadly. Side effects from the immune cells are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA METASTATIC PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

University of Virginia

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.